BioCryst Pharmaceuticals Inc.

17.26+0.2900+1.71%Vol 3.22M1Y Perf 278.99%
Jul 23rd, 2021 16:00 DELAYED
BID17.26 ASK17.40
Open17.09 Previous Close16.97
Pre-Market- After-Market17.35
 - -  0.09 0.52%
Target Price
15.75 
Analyst Rating
Strong Buy 1.00
Potential %
-8.75 
Finscreener Ranking
★+     43.05
Insiders Trans % 3/6/12 mo.
-100/-100/-82 
Value Ranking
★★     47.92
Insiders Value % 3/6/12 mo.
-100/-100/-88 
Growth Ranking
★+     41.53
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-73 
Income Ranking
 —    -
Market Cap3.07B 
Earnings Rating
Neutral
Price Range Ratio 52W %
96.68 
Earnings Date
5th Aug 2021

Today's Price Range

16.7617.61

52W Range

3.3017.74

5 Year PE Ratio Range

-5.40-9.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
10.57%
1 Month
1.53%
3 Months
42.29%
6 Months
87.40%
1 Year
278.99%
3 Years
195.55%
5 Years
460.39%
10 Years
343.70%

TickerPriceChg.Chg.%
BCRX17.260.29001.71
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
2.60
2.70
0.48
2.40
-7.60
Leverage Ratio -6.50
ProfitabilityValueIndustryS&P 500US Markets
76.50
-577.70
-575.50
-442.00
-
RevenueValueIndustryS&P 500US Markets
29.18M
0.16
-3.86
0.20
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.26-0.36-38.46
Q04 2020-0.25-0.34-36.00
Q03 2020-0.25-0.26-4.00
Q02 2020-0.28-0.2414.29
Q01 2020-0.26-0.247.69
Q04 2019-0.25-0.0292.00
Q03 2019-0.31-0.34-9.68
Q02 2019-0.31-0.34-9.68
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.224.35Positive
9/2021 QR-0.253.85Positive
12/2021 FY-1.10-6.80Negative
12/2022 FY-0.74-12.12Negative
Next Report Date5th Aug 2021
Estimated EPS Next Report-0.22
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume3.22M
Shares Outstanding177.70M
Trades Count23.14K
Dollar Volume81.41M
Avg. Volume5.16M
Avg. Weekly Volume2.90M
Avg. Monthly Volume3.04M
Avg. Quarterly Volume3.53M

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock closed at 17.26 per share at the end of the most recent trading day (a 1.71% change compared to the prior day closing price) with a volume of 3.23M shares and market capitalization of 3.07B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 140 people. BioCryst Pharmaceuticals Inc. CEO is Jon P. Stonehouse.

The one-year performance of BioCryst Pharmaceuticals Inc. stock is 278.99%, while year-to-date (YTD) performance is 131.68%. BCRX stock has a five-year performance of 460.39%. Its 52-week range is between 3.3 and 17.74, which gives BCRX stock a 52-week price range ratio of 96.68%

BioCryst Pharmaceuticals Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 56.59, a price-to-sale (PS) ratio of 93.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -97.50%, a ROC of -96.99% and a ROE of 589.25%. The company’s profit margin is -%, its EBITDA margin is -575.50%, and its revenue ttm is $29.18 Million , which makes it $0.16 revenue per share.

Of the last four earnings reports from BioCryst Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. BioCryst Pharmaceuticals Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for BioCryst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $15.75, which is -8.75% compared to the current price. The earnings rating for BioCryst Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioCryst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioCryst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 24.03, ATR14 : 0.76, CCI20 : 204.56, Chaikin Money Flow : 0.16, MACD : 0.24, Money Flow Index : 46.84, ROC : 8.62, RSI : 62.98, STOCH (14,3) : 86.22, STOCH RSI : 1.00, UO : 59.85, Williams %R : -13.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioCryst Pharmaceuticals Inc. in the last 12-months were: Alane Barnes (Option Excercise at a value of $823 123), Alane Barnes (Sold 157 744 shares of value $1 627 441 ), Anthony Doyle (Buy at a value of $220 320), George B. Abercrombie (Option Excercise at a value of $30 684), George B. Abercrombie (Sold 18 667 shares of value $260 021 ), Jon P. Stonehouse (Option Excercise at a value of $557 254), Jon P. Stonehouse (Sold 134 278 shares of value $1 117 193 ), Michael L. Jones (Option Excercise at a value of $15 795), William P. Sheridan (Option Excercise at a value of $171 188), William P. Sheridan (Sold 41 250 shares of value $477 263 ), Yarlagadda S. Babu (Option Excercise at a value of $207 500)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
6 (85.71 %)
6 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (14.29 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.29
Strong Buy
1.50

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

CEO: Jon P. Stonehouse

Telephone: +1 919 859-1302

Address: 4505 Emperor Boulevard, Durham 27703, NC, US

Number of employees: 140

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

News

Stocktwits